After months of intrigue and intense political jockeying, the European Council voted on Monday to relocate Europe’s top medicines regulator to Amsterdam from London.

The close vote — a coin toss was needed — means the European Medicines Agency is likely to encounter less disruption than if Milan, the runner-up, had been chosen. A recent survey of agency staffers favored Amsterdam for its superior international flight service and schools, suggesting the EMA will be able to retain enough staff to maintain regular activities during the upcoming transition.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy